Abstract: Novel crystalline forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3?-methyl-2?-(pentanoyl{2?-(tetrazol-5-ylate)biphenyl-4?-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.

Abstract: The present disclosure relates to crystalline Form 1, Form 2, Form 3 of Ponesimod, a selective S1P1 receptor modulator, and preparation methods thereof. The X-ray powder diffraction pattern of Form 1 shows characteristic peaks at 2theta values of 18.1°±0.2°, 14.6°±0.2°, 11.3°±0.2°; the X-ray powder diffraction pattern of Form 2 shows characteristic peaks at 2theta values of 3.8°±0.2°, 10.8°±0.2°, 6.1°±0.2°; the X-ray powder diffraction pattern of Form 3 shows characteristic peaks at 2theta values of 12.2°±0.2°, 6.2°±0.2°, 5.6°±0.2°. The crystalline forms in present disclosure not only have better stability but also have higher solubility compared with the prior art forms, they are more suitable for the formulation development of Ponesimod.

Abstract: The present disclosure relates to novel crystalline forms of VX-787, processes for preparation thereof and use thereof. VX-787 is a viral-protein inhibitor drug. The present disclosure provides crystalline form CS1, crystalline form CS2, crystalline form CS3, and crystalline form CS4 of compound (I) hydrochloride. The present disclosure also provides crystalline form CS3 and crystalline form CS9 of compound (I).free form.

Abstract: The present disclosure relates to crystalline Form 1, Form 2, Form 3 of Ponesimod, a selective S1P1 receptor modulator, and preparation methods thereof. The X-ray powder diffraction pattern of Form 1 shows characteristic peaks at 2theta values of 18.1°±0.2°, 14.6°±0.2°, 11.3°±0.2°; the X-ray powder diffraction pattern of Form 2 shows characteristic peaks at 2theta values of 3.8°±0.2°, 10.8°±0.2°, 6.1°±0.2°; the X-ray powder diffraction pattern of Form 3 shows characteristic peaks at 2theta values of 12.2°±0.2°, 6.2°±0.2°, 5.6°±0.2°. The crystalline forms in present disclosure not only have better stability but also have higher solubility compared with the prior art forms, they are more suitable for the formulation development of Ponesimod.

Abstract: The present disclosure relates to novel crystalline form I, form II and form III of 6-(1H-indazol-6-yl)-N-[4-(4-morpholinyl)phenyl]imidazo [1,2-a]pyrazin-8-amine mesylate, and preparation methods and use thereof. Crystalline form I is a dimesylate, and its X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 5.9°±0.2°, 13.5°±0.2° and 21.8°±0.2°. Crystalline form II is a dimesylate, and its X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 15.8°±±0.2°, 17.2°±0.2° and 19.5°±0.2°. Crystalline form III is a monomesylate, and its X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 7.4°±0.2°, 12.9°±0.2° and 19.2°±0.2°. The crystalline forms are more suitable for drug development than prior crystalline forms, and the preparation methods for the crystalline forms are simple and repeatable and have significant value for future drug optimization and development.

Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Abstract: The present disclosure relates to novel crystalline forms of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-4(3H)-one and processes for preparation and use thereof, relating to pharmaceutical industry. Form CS2, Form CS8, Form CS13, Form CS20, Form CS1, Form CS7, Form CS9, Form CS11 and Form CS4 of the present disclosure can be used for preparing drugs treating cardiovascular, cholesterol or lipid-related disorders.

Abstract: The present disclosure relates to two novel crystalline forms of AP26113 and processes for preparation thereof. The crystalline form CS1 and crystalline form CS2 of the present disclosure have advantages in solubility and stability, are suitable for development, and provide a better choice for preparation of pharmaceutical compositions containing AP26113, which is of great significance for drug development.

Abstract: The present disclosure relates to a preparation method of a trisodium AHU-377 and Valsartan co-crystal hydrate Form II. The preparation method comprises: firstly, preparing a clear solution of trisodium AHU-377 and Valsartan, the solvent of the clear solution comprises an anti-solvent and a good solvent of the target product Form II, and the boiling point of the good solvent is lower than that of the anti-solvent; secondly, evaporating the solution under vacuum to remove the good solvent and water from the system; and finally, optionally adding seed crystals of Form II or not and replenishing a mixture of water and a carrier solvent for stirring for crystallization. The method of the present disclosure can prepare Form II successfully, and the process is consistent and controllable. The obtained Form II product has high chemical purity, crystalline purity and good flowability; and the process can be scaled up, and meets the requirements of large-scale production.

Abstract: The present disclosure relates to novel crystalline forms of NBI-98854 (as shown in formula I), preparation process and use thereof. The crystalline forms of NBI-98854 provided by the present disclosure, named as Form CS1 and Form CS2, can be used for preparing drug product treating tardive dyskinesia. The crystalline forms of NBI-98854 provided by the present disclosure have pharmaceutically acceptable solubility and hygroscopicity, good stability and are stable during storage, thereby avoiding changes in drug solubility, dissolution rate, bioavailability and efficacy due to polymorph transformation. This provides a new and better choice for the preparation of drug product containing NBI-98854, which has significant value for future drug development.

Abstract: The present disclosure relates to novel crystalline forms of PLX3397 hydrochloride and processes for preparation thereof. The crystalline forms of PLX3397 hydrochloride provided by the present disclosure have higher solubility, larger particle size which is favorable for separation in the subsequent production process, and good stability, especially mechanical stability. These novel crystalline forms of PLX3397 hydrochloride provide a better choice for PLX3397 drug products and are of great value for drug development.

Abstract: An optical fiber including a light guiding inner core. The light guiding inner core includes a first light guiding segment and a second light guiding segment connected to the first light guiding segment. The first light guiding segment includes, from the inside out, a light absorbing layer, an inner electrode layer, an insulating layer, a void layer, a proton exchange membrane, and an outer electrode layer. The void layer is formed between the insulating layer and the proton exchange membrane. The light absorbing layer is a photovoltaic material layer. The inner electrode layer communicates with the proton exchange membrane via a plurality of microelectrodes across the insulating layer and the void layer. The plurality of microelectrodes is evenly disposed around the inner electrode layer. The outer electrode layer is a porous conductive structure. The second light guiding segment of the light guiding inner core includes a conductive layer.

Abstract: The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof.

Abstract: The present disclosure relates to novel crystalline forms of JAK inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis. The novel crystalline forms in the present disclosure have good stability and remarkable purification effect in process, moreover, its solubility and hygroscopicity meet the requirements for medical use. The preparation method of novel crystalline forms is simple, low cost, and has an important value for future optimization and development of the drug.

Abstract: The present disclosure relates to a novel crystalline form of Galunisertib, processes for preparation and use thereof. The present disclosure also relates to a pharmaceutical composition comprises the novel crystalline form of Galunisertib and use of the novel crystalline form of Galunisertib and pharmaceutical composition for preparing drugs treating disease. The crystalline form of the present disclosure has good stability, solubility and hygroscopicity, which has significant value for future drug optimization and development.

Abstract: The present disclosure relates to novel crystalline forms of NBI-98854 (as shown in formula I), preparation process and use thereof. The crystalline forms of NBI-98854 provided by the present disclosure, named as Form CS1 and Form CS2, can be used for preparing drug product treating tardive dyskinesia. The crystalline forms of NBI-98854 provided by the present disclosure have pharmaceutically acceptable solubility and hygroscopicity, good stability and are stable during storage, thereby avoiding changes in drug solubility, dissolution rate, bioavailability and efficacy due to polymorph transformation. This provides a new and better choice for the preparation of drug product containing NBI-98854, which has significant value for future drug development.

Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.

Abstract: Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

Abstract: A gasifier, including a vertically disposed furnace body, a monitoring unit, and a microwave plasma generating device. The furnace body includes a material and fuel inlet, a syngas outlet, an oxygen/vapor inlet, and a slag outlet. The furnace body has a clearance zone in an upper part thereof and a fixed bed zone in a lower part thereof. The slag outlet is disposed at the bottom of the furnace body. The monitoring unit is disposed close to the syngas outlet. At least one microwave plasma generating device is disposed on the furnace body.

Abstract: A method for drying biomass fuel using waste heat of flue gas from a power plant. The method includes: 1) stepwise recovering, by multi-stage condensation, sensible heat of flue gas; stepwise heating air using the sensible heat, to yield first-stage dry air and second-stage dry air; 2) convectively drying and dehydrating biomass fuel using the first-stage dry air having a temperature of between 150 and 180° C.; 3) further convectively drying and dehydrating the biomass fuel using the second-stage dry air having a temperature of between 80 and 100° C.; and 4) drying and dehydrating the biomass fuel using the third-stage dry air having a temperature of less than or equal to 25° C.